Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

As a participant in all three editions of the supply chain expo, Novo Nordisk is joining more industrial chain partners this year to build a comprehensive health management ecosystem that drives ...

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The company’s shares closed yesterday at CHF92.29. Evans ...

Health Canada has issued a recall for a lot of Ozempic after discovering that some units may have cracked glass in the medication packaging, which could lead to contamination or injury if used. The ...

While the North Chicago, Illinois-based healthcare giant estimated its adjusted diluted earnings per share for Q3 could reach $1.28 - $1.32 compared to $1.33 in the consensus, its full-year outlook ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...